Skip to main content
Erschienen in:

01.09.2011 | Leitthema

Aktuelle Therapiestrategien bei follikulären Lymphomen

verfasst von: C. Schmidt, K. Herfarth, Prof. Dr. W. Hiddemann

Erschienen in: Die Onkologie | Ausgabe 9/2011

Einloggen, um Zugang zu erhalten

Zusammenfassung

Follikuläre Lymphome sind nach den diffus-großzelligen B-Zell-Lymphomen die zweithäufigste Lymphomentität. Ihr klinischer Verlauf ist in der Regel langsam progredient, sodass sie zu den indolenten Lymphomen gezählt werden. Bei den wenigen Patienten, bei denen die Erkrankung in einem frühen Stadium I oder II diagnostiziert wird, ist eine Strahlentherapie indiziert. In den fortgeschrittenen Stadien III und IV ist bei fehlender klinischer Symptomatik eine Watch-and-wait-Strategie angezeigt. Bei Vorliegen einer Behandlungsindikation ist eine Immunchemotherapie mit nachfolgender 2-jähriger Erhaltungstherapie mit Rituximab aktueller Standard.
Literatur
1.
Zurück zum Zitat Advani R, Rosenberg SA, Horning SJ (2004) Stage I and II follicular non-Hodgkin’s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 22:1454–1459PubMedCrossRef Advani R, Rosenberg SA, Horning SJ (2004) Stage I and II follicular non-Hodgkin’s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 22:1454–1459PubMedCrossRef
2.
Zurück zum Zitat Ardeshna KM, Qian W, Smith P et al (2010) An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (Grades 1, 2 and 3a). A preliminary analysis. ASH Annual Meeting Abstracts 116:6 Ardeshna KM, Qian W, Smith P et al (2010) An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (Grades 1, 2 and 3a). A preliminary analysis. ASH Annual Meeting Abstracts 116:6
3.
Zurück zum Zitat Ardeshna KM, Smith P, Norton A et al (2003) Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 362:516–522PubMedCrossRef Ardeshna KM, Smith P, Norton A et al (2003) Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 362:516–522PubMedCrossRef
4.
Zurück zum Zitat Buske C, Hoster E, Dreyling M et al (2006) The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 108:1504–1508PubMedCrossRef Buske C, Hoster E, Dreyling M et al (2006) The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 108:1504–1508PubMedCrossRef
5.
Zurück zum Zitat Colombat P, Salles G, Brousse N et al (2001) Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97:101–106PubMedCrossRef Colombat P, Salles G, Brousse N et al (2001) Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97:101–106PubMedCrossRef
6.
Zurück zum Zitat Deconinck E, Foussard C, Milpied N et al (2005) High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 105:3817–3823PubMedCrossRef Deconinck E, Foussard C, Milpied N et al (2005) High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 105:3817–3823PubMedCrossRef
7.
Zurück zum Zitat Dreyling M (2009) Newly diagnosed and relapsed follicular lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):119–120PubMedCrossRef Dreyling M (2009) Newly diagnosed and relapsed follicular lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):119–120PubMedCrossRef
8.
Zurück zum Zitat Dreyling M, Trumper L, Von Schilling C et al (2007) Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma – role of radioimmunotherapy. Ann Hematol 86:81–87PubMedCrossRef Dreyling M, Trumper L, Von Schilling C et al (2007) Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma – role of radioimmunotherapy. Ann Hematol 86:81–87PubMedCrossRef
9.
Zurück zum Zitat Forstpointner R, Unterhalt M, Dreyling M et al (2006) Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108:4003–4008PubMedCrossRef Forstpointner R, Unterhalt M, Dreyling M et al (2006) Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108:4003–4008PubMedCrossRef
10.
Zurück zum Zitat Fowler NH, Mclaughlin P, Hagemeister FB et al (2010) Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin’s lymphoma. ASCO Meeting Abstracts 28:8036 Fowler NH, Mclaughlin P, Hagemeister FB et al (2010) Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin’s lymphoma. ASCO Meeting Abstracts 28:8036
11.
Zurück zum Zitat Gyan E, Foussard C, Bertrand P et al (2009) High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 yrs. Blood 113:995–1001PubMedCrossRef Gyan E, Foussard C, Bertrand P et al (2009) High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 yrs. Blood 113:995–1001PubMedCrossRef
12.
Zurück zum Zitat Harris NL, Jaffe ES, Diebold J et al (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835–3849PubMed Harris NL, Jaffe ES, Diebold J et al (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835–3849PubMed
13.
Zurück zum Zitat Herold M, Haas A, Srock S et al (2007) Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 25:1986–1992PubMedCrossRef Herold M, Haas A, Srock S et al (2007) Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 25:1986–1992PubMedCrossRef
14.
Zurück zum Zitat Hiddemann W, Kneba M, Dreyling M et al (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725–3732PubMedCrossRef Hiddemann W, Kneba M, Dreyling M et al (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725–3732PubMedCrossRef
15.
Zurück zum Zitat Hochster H, Weller E, Gascoyne RD et al (2009) Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 27:1607–1614PubMedCrossRef Hochster H, Weller E, Gascoyne RD et al (2009) Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 27:1607–1614PubMedCrossRef
16.
Zurück zum Zitat Kaminski MS, Tuck M, Estes J et al (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352:441–449PubMedCrossRef Kaminski MS, Tuck M, Estes J et al (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352:441–449PubMedCrossRef
17.
Zurück zum Zitat Ladetto M, De Marco F, Benedetti F et al (2008) Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 111:4004–4013PubMedCrossRef Ladetto M, De Marco F, Benedetti F et al (2008) Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 111:4004–4013PubMedCrossRef
18.
Zurück zum Zitat Lenz G, Dreyling M, Schiegnitz E et al (2004) Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104:2667–2674PubMedCrossRef Lenz G, Dreyling M, Schiegnitz E et al (2004) Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104:2667–2674PubMedCrossRef
19.
Zurück zum Zitat Marcus R, Imrie K, Solal-Celigny P et al (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26:4579–4586PubMedCrossRef Marcus R, Imrie K, Solal-Celigny P et al (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26:4579–4586PubMedCrossRef
20.
Zurück zum Zitat Morschhauser F, Radford J, Van Hoof A et al (2008) Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26:5156–5164PubMedCrossRef Morschhauser F, Radford J, Van Hoof A et al (2008) Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26:5156–5164PubMedCrossRef
21.
Zurück zum Zitat Robert-Koch-Institut GDEKIDEVIZMD (2006) Krebs in Deutschland – Häufigkeiten und Trends. In: Robert-Koch-Institut GDEKIDEVIZMD (2006) Krebs in Deutschland – Häufigkeiten und Trends. In:
22.
Zurück zum Zitat Rohatiner AZ, Gregory WM, Peterson B et al (2005) Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 23:2215–2223PubMedCrossRef Rohatiner AZ, Gregory WM, Peterson B et al (2005) Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 23:2215–2223PubMedCrossRef
23.
Zurück zum Zitat Rummel MJ, Niederle N, Maschmeyer G et al (2009) Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the stil (Study Group Indolent Lymphomas, Germany). Blood (ASH Annual Meeting Abstracts) 114:405 Rummel MJ, Niederle N, Maschmeyer G et al (2009) Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the stil (Study Group Indolent Lymphomas, Germany). Blood (ASH Annual Meeting Abstracts) 114:405
24.
Zurück zum Zitat Salles G, Mounier N, De Guibert S et al (2008) Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 112:4824–4831PubMedCrossRef Salles G, Mounier N, De Guibert S et al (2008) Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 112:4824–4831PubMedCrossRef
25.
Zurück zum Zitat Salles G, Seymour JF, Offner F et al (2011) Rituximab maintenance for 2 yrs in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377:42–51PubMedCrossRef Salles G, Seymour JF, Offner F et al (2011) Rituximab maintenance for 2 yrs in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377:42–51PubMedCrossRef
26.
Zurück zum Zitat Schulz H, Bohlius JF, Trelle S et al (2007) Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 99:706–714PubMedCrossRef Schulz H, Bohlius JF, Trelle S et al (2007) Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 99:706–714PubMedCrossRef
27.
Zurück zum Zitat Seer CSR (2007) SEER Surveillance, Epidemiology, and End Results. In: 1975–2004. SEER Cancer Stat Rev Seer CSR (2007) SEER Surveillance, Epidemiology, and End Results. In: 1975–2004. SEER Cancer Stat Rev
28.
Zurück zum Zitat Seymour JF, Pro B, Fuller LM et al (2003) Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin’s lymphoma. J Clin Oncol 21:2115–2122PubMedCrossRef Seymour JF, Pro B, Fuller LM et al (2003) Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin’s lymphoma. J Clin Oncol 21:2115–2122PubMedCrossRef
29.
Zurück zum Zitat Sinha R, Kaufman JL, Khoury HJ Jr et al (2009) The addition of bortezomib to modified R-CHOP as initial therapy for follicular NHL results in high CR rate and is well tolerated. Blood (ASH Annual Meeting Abstracts) 114:3718- Sinha R, Kaufman JL, Khoury HJ Jr et al (2009) The addition of bortezomib to modified R-CHOP as initial therapy for follicular NHL results in high CR rate and is well tolerated. Blood (ASH Annual Meeting Abstracts) 114:3718-
30.
Zurück zum Zitat Solal-Celigny P, Roy P, Colombat P et al (2004) Follicular lymphoma international prognostic index. Blood 104:1258–1265PubMedCrossRef Solal-Celigny P, Roy P, Colombat P et al (2004) Follicular lymphoma international prognostic index. Blood 104:1258–1265PubMedCrossRef
31.
Zurück zum Zitat Stuschke M, Hoederath A, Sack H et al (1997) Extended field and total central lymphatic radiotherapy in the treatment of early stage lymph node centroblastic-centrocytic lymphomas: results of a prospective multicenter study. Study Group NHL-fruhe Stadien. Cancer 80:2273–2284PubMedCrossRef Stuschke M, Hoederath A, Sack H et al (1997) Extended field and total central lymphatic radiotherapy in the treatment of early stage lymph node centroblastic-centrocytic lymphomas: results of a prospective multicenter study. Study Group NHL-fruhe Stadien. Cancer 80:2273–2284PubMedCrossRef
32.
Zurück zum Zitat Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues
33.
Zurück zum Zitat Van Oers MH, Klasa R, Marcus RE et al (2006) Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 108:3295–3301CrossRef Van Oers MH, Klasa R, Marcus RE et al (2006) Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 108:3295–3301CrossRef
34.
Zurück zum Zitat Vidal L, Gafter-Gvili A, Leibovici L et al (2009) Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 101:248–255PubMedCrossRef Vidal L, Gafter-Gvili A, Leibovici L et al (2009) Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 101:248–255PubMedCrossRef
35.
Zurück zum Zitat Witzens-Harig M, Hensel M, Unterhalt M et al (2011) Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial. BMC Cancer 11:87PubMedCrossRef Witzens-Harig M, Hensel M, Unterhalt M et al (2011) Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial. BMC Cancer 11:87PubMedCrossRef
36.
Zurück zum Zitat Witzig TE, Gordon LI, Cabanillas F et al (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20:2453–2463PubMedCrossRef Witzig TE, Gordon LI, Cabanillas F et al (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20:2453–2463PubMedCrossRef
37.
Zurück zum Zitat Yang E, Korsmeyer SJ (1996) Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 88:386–401PubMed Yang E, Korsmeyer SJ (1996) Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 88:386–401PubMed
Metadaten
Titel
Aktuelle Therapiestrategien bei follikulären Lymphomen
verfasst von
C. Schmidt
K. Herfarth
Prof. Dr. W. Hiddemann
Publikationsdatum
01.09.2011
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 9/2011
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-011-2128-3

Weitere Artikel der Ausgabe 9/2011

Die Onkologie 9/2011 Zur Ausgabe

Einführung zum Thema

Das Bessere ist des Guten Feind

Neu im Fachgebiet Onkologie

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Endometriose-Subtypen und das Risiko für Ovarialkarzinome

19.07.2024 Ovarialkarzinom Nachrichten

US-Kohortendaten sprechen dafür, dass verschiedene Endometrioseformen unterschiedlich mit dem Risiko für Ovarialkarzinome assoziiert sind. Besonders erhöht ist das Risiko offenbar bei tief infiltrierenden und ovariellen Endometrioseformen.

Die zelluläre Differenzierung wird wiederhergestellt

18.07.2024 Akute myeloische Leukämie Nachrichten

Ivosidenib von Servier ist ein Inhibitor der mutierten Isoform der Isocitrat-Dehydrogenase-1 (IDH1) und wird zur Behandlung von Patientinnen und Patienten mit neu diagnostizierter akuter myeloischer Leukämie (AML) eingesetzt. Die Substanz sorgt für die Wiederherstellung der zellulären Differenzierung.

Weißer Hautkrebs: Ein Update zu Diagnostik und Therapie

18.07.2024 Fortbildungswoche 2024 Kongressbericht

In der aktualisierten Version der S3-Leitlinie „Aktinische Keratose und Plattenepithelkarzinom der Haut“ gibt es neue Empfehlungen, unter anderem zu erweiterten Optionen bei aktinischer Keratose sowie zur systemischen und chirurgischen Behandlung von Plattenepithelkarzinomen. Ein Überblick.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.